Navigation Links
Navigenics'(TM) Genome Analysis Used In Research Trial on the Impact of Providing Genetic Risk Assessments
Date:4/8/2008

REDWOOD SHORES, Calif., April 8, 2008 /PRNewswire/ -- Navigenics, a genetic health services company, today announced a new study of genetic predisposition analysis. The Mayo Clinic study will examine how patients understand and use information provided by a Navigenics genetic risk assessment. The research also addresses physicians' understanding of genetic assessments and the impact of such information on preventive health decision making. Titled "A Proof of Principle Trial of Communication to Patients Receiving Predictive Genetic Risk Assessment," the study begins this month and runs through September 2009. The study is funded jointly by Navigenics and Mayo Clinic.

"In this emerging field it is absolutely critical that the entire industry remain rooted in high-quality science and research - this is exactly what we do and what our customers, collaborators and advisors expect from Navigenics," said Mari Baker, president and CEO of Navigenics. "We believe this research collaboration with a leading medical institution like Mayo Clinic will help the entire industry evolve responsibly, provide the necessary tools to educate clinicians, and ultimately improve people's lives."

The Navigenics(TM) Health Compass is a new genetic risk assessment service that combines an advanced genome scan with the latest discoveries in genetic medicine and personalized genetic counseling. It gives individuals information on their genetic predisposition to developing a broad menu of common conditions, so that, with their physicians, they can seek earlier diagnosis, delay the onset or prevent the conditions altogether. The service calculates genetic predisposition based on genome-wide association studies that combine a variety of epidemiological variables. Navigenics scours the more than 4,000 published studies correlating genes to medical conditions and other common human traits to include only those which present high-quality and reliable results. The Navigenics Health
'/>"/>

SOURCE Navigenics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
2. Human Genome Sciences Presents New Data Showing Anti-Tumor Activity And Safety Of Trail Receptor Antibodies In Combination With Chemotherapy
3. Human Genome Sciences Announces Full Presentation of Quality-of-Life Results From Phase 2b Trial of Albuferon(R) for Hepatitis C
4. Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy
5. Human Genome Sciences Announces Presentation at AASLD of Results of Phase 2b Trial of Albuferon(R) for Chronic Hepatitis C
6. Human Genome Sciences Reports Positive Data from Long-Term Treatment with LymphoStat-B(R) in Patients with Active Systemic Lupus Erythematosus
7. Human Genome Sciences Modifies Dosing in Achieve Trials of Albuferon(R)
8. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
9. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
10. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
11. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... July 25, 2014 /PRNewswire-iReach/ -- "Australia Capsule Endoscopy Systems ... the Australia Capsule Endoscopy Systems market. The report provides ... and average prices (in US dollars) within market segments: ... , Capsule Endoscopes , Capsule Endoscopy Data ... The report also provides company shares and distribution shares ...
(Date:7/25/2014)... 25, 2014 /PRNewswire-iReach/ -- ScriptPro, of ... Powers Lake, Wisconsin , announce that ... and co-marketing agreement allowing ScriptPro to bring TCGRx ... the United States . ScriptPro is ... workflow systems to retail and ambulatory pharmacies. TCGRx ...
(Date:7/25/2014)... , July 25, 2014 GrowBLOX Sciences, Inc. ... binding Memorandum of Understanding ("MOU") with LaurelCo, LLC, an ... the acquisition of both cultivation and dispensary medical marijuana licenses ... to the MOU, GBLX will acquire a 20% equity interest ... proprietary GrowBLOX TM growing chambers, as well as all ...
Breaking Medicine Technology:Australia Capsule Endoscopy Systems Market Analysis and Forecast to 2020 2Australia Capsule Endoscopy Systems Market Analysis and Forecast to 2020 3Australia Capsule Endoscopy Systems Market Analysis and Forecast to 2020 4Australia Capsule Endoscopy Systems Market Analysis and Forecast to 2020 5ScriptPro and TCGRx Integrate Pharmacy Automation Technologies 2ScriptPro and TCGRx Integrate Pharmacy Automation Technologies 3GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 2GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 3
... Texas--(BUSINESS WIRE)--Apr 3, 2007 - Repros,Therapeutics Inc. (NasdaqGM:RPRX) ... of Proellex(TM), an oral drug being developed to,relieve ... with Proellex results in a statistically highly,significant improvement ... well tolerated., Study Details and Results , This ...
... 03, 2007,/PRNewswire-FirstCall/ -- Cell Genesys, Inc. today ... Phase 2 trial of GVAX,immunotherapy for prostate ... in 80 patients with metastatic,hormone-refractory prostate cancer ... received the dose that is comparable to ...
Cached Medicine Technology:Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 2Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 3Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 4Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 5Cell Genesys Provides Final Median Survival Data From Second Phase,2 Trial of GVAX Immunotherapy for Prostate Cancer 2Cell Genesys Provides Final Median Survival Data From Second Phase,2 Trial of GVAX Immunotherapy for Prostate Cancer 3
(Date:7/25/2014)... 2014 The Little Gym of Houston ... Sunday, July 27 at Discovery Green in downtown Houston. ... Katy, Pearland, Friendswood, Spring, The Woodlands, Sugarland-Missouri City, Kingwood, ... , “We’re thrilled to be attending and performing at ... who owns the Sugarland-Missouri City location. “We believe in ...
(Date:7/25/2014)... AttorneyOne.com, a recognized authority on law, update the website ... Ibuprofen and Oxcarbazepine Tablets . , The FDA ... one lot of Oxcarbazepine Tablets, by American Health Packaging (AHP), ... used for the treatment of certain types of seizures in ... recall is that Lot #142588, Expiration Date, 01/2016 of Ibuprofen ...
(Date:7/25/2014)... Ticket Down is a reliable ... in Berkeley at California Memorial Stadium. With the post-World ... football, the organizers of the 2014 Guinness International Champions Cup ... North America. With teams representing La Liga, English Premier League, ... of the best football players from around the world to ...
(Date:7/25/2014)... 2014 On July 22, 2014, ... client and the nation’s number one provider of ... announced their partnership with TransAct Merchant Solutions’ National ... ISO/MSP of Chase Paymentech Solutions, LLC, which provides ... Companies that are members of TransAct’s National Association ...
(Date:7/25/2014)... Hastings and Hastings, a personal injury ... to personal injury claims, announces free initial consultations. Hastings ... services for those that have been injured as a ... Free initial consultation services gives clients’ greater flexibility in ... personal injury claim . It also offers clients the ...
Breaking Medicine News(10 mins):Health News:The Little Gym of Houston to Attend Houston Family Magazine’s Family Fun Fest 2014 2Health News:Ibuprofen and Oxcarbazepine Tablets Recalled: AttorneyOne Monitors and Keep Consumers Informed 2Health News:Real Madrid vs. Inter Milan Tickets Berkeley: Ticket Down Slashes Ticket Prices on Guinness International Champions Cup Tickets at California Memorial Stadium 2Health News:Real Madrid vs. Inter Milan Tickets Berkeley: Ticket Down Slashes Ticket Prices on Guinness International Champions Cup Tickets at California Memorial Stadium 3Health News:Nuanced Media Client, CEDR HR Solutions, Partners with TransAct to Serve Medical, Dental, and Eye Care Professionals 2Health News:Hastings and Hastings Announces Complimentary Consultation Services 2Health News:Hastings and Hastings Announces Complimentary Consultation Services 3
... A long-running Merck ad featured an older woman with this message: ... be?" and recommended that women ask their doctors about bone ... Merck's drug Fosamax. But this very drug, (generic name alendronate) turned ... the risk of hip fracture from 2 percent to 1 percent, ...
... the time of Chaucer were not dwarfs but only short ... was the case with women more or less, a new ... revealed. ,As part of their study, scientists researched ... upon Humber, North East Lincolnshire, and found that the average ...
... engineered adult stem cells from human umbilical cord blood to ... type 1 diabetes by allowing people to grow their own ... ,The study was conducted by a team of researchers led ... Branch at Galveston. ,As part of the study, ...
... has decided to send youths to learn meditation from Indian ... visit to the war-hit country Thursday with a trip ... the Art of Living Foundation, Iraqi Youth Minister Jasin Mohammed ... of Iraq to Bangalore to undergo the group's Youth Leadership ...
... Abdul Kalam Friday urge the nation's doctors to work for ... Post-Graduate Institute of Medical Sciences in Rohtak, Kalam called upon ... ,If each doctor showed the zeal to treat at ... lot of diseases could be taken care of. ...
... by the American Academy of Neurology finds conventionally recommended ... system Lyme disease. However, there is no compelling ... in treating symptoms that persist following standard therapy. The ... edition of Neurology, the scientific journal of the American ...
Cached Medicine News:Health News:Women Urged to Be Wary of Ads Promoting Unwanted Drugs 2Health News:Women Urged to Be Wary of Ads Promoting Unwanted Drugs 3Health News:Our Medieval Ancestors Were More or Less Similar to Us Than Previously Thought 2Health News:Art of Living Foundation to Train Iraqi Youths 2Health News:Antibiotics Highly Effective for Treating Lyme Disease 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Bausch & Lomb PreserVision® Soft Gel ... clinically proven Bausch & Lomb PreserVision® AREDS ... mg of FloraGlo Lutein., Lutein is a ... such as spinach. Lutein is highly concentrated ...
... a scientifically advanced multinutrient that ... and full body health. It ... including a diverse array of ... lycopene and OptiBerry and important ...
Medicine Products: